Jiangsu Hengrui Medicine

Historical price data

Jiangsu Hengrui Medicine's mission is to advance healthcare through high-quality, innovative medicines, solidifying its position as China's largest and most valuable pharmaceutical company. Its key achievements include building a massive pipeline of 719 drug candidates, successfully launching multiple blockbuster oncology drugs in China, and establishing international R&D footprints. The company's strategy centers on aggressive investment in proprietary R&D, a dual-track approach of 'innovation + internationalization,' and dominating key therapeutic areas like oncology while expanding into metabolic, autoimmune, and neurological diseases.

A fully integrated suite of proprietary platforms including advanced small-molecule discovery, monoclonal & bispecific antibody engineering, a next-generation Antibody-Drug Conjugate (ADC) platform with proprietary linker-payload technology, and protein degradation (PROTAC) capabilities.